Supernus Pharmaceuticals
SUPN
320 hedge funds and large institutions have $3.21B invested in Supernus Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 112 increasing their positions, 120 reducing their positions, and 37 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
37% more capital invested
Capital invested by funds: $2.34B → $3.21B (+$865M)
24% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 37
4.15% more ownership
Funds ownership: 99.38% → 103.53% (+4.1%)
3% more funds holding
Funds holding: 312 → 320 (+8)
7% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 120
50% less call options, than puts
Call options by funds: $16.7M | Put options by funds: $33.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.3M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$42.8M |
| 3 |
BlackRock
New York
|
+$32.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$30.6M |
| 5 |
Renaissance Technologies
New York
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$26.5M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$25.9M |
| 3 |
JP Morgan Chase
New York
|
-$13.6M |
| 4 |
Millennium Management
New York
|
-$13.5M |
| 5 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$11.5M |
SUPN Hedge Fund Activity: Q2 2018 in Review
320 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2018, worth a combined $3.21B — up 37% from $2.34B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new SUPN positions and 37 closed out — a net gain of 9 holders — while 112 added to existing stakes and 120 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $46.3M. The largest seller was Russell Investments Group, cutting an estimated $26.5M.
- 320 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2018, up from 312 in Q1 2018.
- Funds reported $3.21B of Supernus Pharmaceuticals stock for Q2 2018, up 37% quarter-over-quarter.
- 46 funds opened new Supernus Pharmaceuticals positions in Q2 2018 and 37 closed out, a net change of +9 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2018 was Fidelity Investments, an estimated $46.3M added.
- The largest Supernus Pharmaceuticals seller in Q2 2018 was Russell Investments Group, an estimated $26.5M sold.
Based on aggregated 13F filings for Q2 2018.